Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients by Xueting Hou, Jizhang Bao

“…Acute myelogenous leukemia(AML) is a life-threatening hematologic malignancy that predominantly affects the elderly.Currently, chemotherapy and hematopoietic stem cell transplantation are the primary treatment modalities for AML, though their clinical application is limited in older patients.Recent years have seen the development of novel molecular targeted therapies, such as isocitrate dehydrogenase 1/2 (IDH1/2) and Feline macrophage stimulator-like tyrosine kinase 3 (FLT3) inhibitors, as well as individualized approaches like chimeric antigen receptor T-cell (CAR-T) therapy.However, due to patient heterogeneity and drug resistance, treatment outcomes for elderly AML remain unsatisfactory, underscoring the need for more precise and safer individualized treatment strategies.The combination of chemotherapy with novel targeted or immunotherapies shows promise as a future treatment direction.This research reviews the latest advances in the treatment of elderly AML, with a focus on achieving more individualized and safer therapeutic approaches.…”
Get full text

Application of Bionanomaterials in Tumor Immune Microenvironment Therapy by Jiawei Wang, Yan Bao, Yandan Yao

“…Immune checkpoint blockade therapy and chimeric antigen receptor T-cell (CAR-T) immunotherapy are clinically effective in a variety of cancers. …”
Get full text

CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES by Ugo Testa, Patrizia Chiusolo, Elvira Pelosi, Germana Castelli, Giuseppe Leone

“… Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes. …”
Get full text

The success of the tumor immunotherapy: neutrophils from bench to beside by Meng Zhu, Ru Jia, Xiaojie Zhang, Pingwei Xu

“…The present immune therapy was focused on the immune checkpoint blockade or Chimeric Antigen Receptor T-Cell Immunotherapy (CART) transfer, but how to activate the innate immune system to antitumor still lags out. …”
Get full text

Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis by Huyen Thi La, Dao Bich Thi Tran, Hai Manh Tran, Linh Trong Nguyen

“…This study designed the chimeric antigen receptor T-cell (CAR-T) to bind to the CD47 to inhibit the expression of CD47. …”
Get full text

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma? by Davor Galusic, Ivan Krecak, Viktor Blaslov, Andela Krstulovic Opara, Toni Valkovic, Sandra Basic Kinda

“…Due to the cost and availability of bispecific T cell redirecting antibodies (BsAbs) and chimeric antigen receptor T cell therapy (CAR-T) in real-life settings in many countries, retreatment with daratumumab in subsequent lines of therapy might be a reasonable choice. …”
Get full text

Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer by Lijuan Qin, Yuan Li, Juan Liu, Xiaoqin An

“…Among the most promising approaches are cellular therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapy, which has shown remarkable success in hematologic malignancies. …”
Get full text

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients by Kamel Ait-Tahar, Amanda P. Anderson, Martin Barnardo, Graham P. Collins, Chris S. R. Hatton, Alison H. Banham, Karen Pulford

“…Success using immune checkpoint inhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. …”
Get full text

Modified CD15/CD16-CLL1 inhibitory CAR-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemia by Rui Zhang, Yifan Zhao, Xiao Chai, Yingshuai Wang, Mohan Zhao, Shujing Guo, Yu Zhang, Mingfeng Zhao

“…CLL1 Chimeric antigen receptor T-cell (CAR-T) therapy, as a promising immunotherapeutic approach, has demonstrated its potential to enhance the prognosis of patients diagnosed with acute myeloid leukemia (AML). …”
Get full text

Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry by Frederick L Locke, Grant Schofield, Marcelo Pasquini, Matthew J Frigault, Cameron J Turtle, Stephen Lim, Brian Hill, Samantha Jaglowski, Caron A Jacobson, Gunjan Shah, Daniel J Landsburg, Michael Heim, Stephen Ronan Foley, Ron Ram, Peter A Riedell, Leslie L Popplewell, Ranjan Tiwari, Marta Majdan, Aisha Masood

“…Background Tisagenlecleucel, a CD19 chimeric antigen receptor T-cell therapy, is approved for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) after ≥2 lines of therapy. …”
Get full text

Efficacy and Safety of CART Cell Therapy in Aggressive B‐Cell Lymphomas Involving the Gastrointestinal Tract by Lixia Ma, Yimeng Dou, Rui Liu, Teng Xu, Fan Yang, Peihao Zheng, Shaomei Feng, Yuelu Guo, Hui Shi, Fei Xue, Biping Deng, Xiaoyan Ke, Kai Hu

“…ABSTRACT Objective Currently, chimeric antigen receptor T‐cell (CART) therapy represents a highly effective approach for relapsed/refractory B‐cell lymphomas. …”
Get full text

Engineering of SauriCas9 with enhanced specificity by Xiaoqi Zhang, Chen Tao, Miaomiao Li, Sufang Zhang, Puping Liang, Yan Huang, Huihui Liu, Yongming Wang

“…To validate its efficacy, we employed SauriCas9-R253A to disrupt three genes (B2M, TRAC, and PDCD1), a strategy integral to the development of allogeneic chimeric antigen receptor T cell (CAR-T) therapies. Our results demonstrated that the most efficient single-guide RNAs for SauriCas9-R253A exhibited comparable activity to SpCas9 and showed no detectable off-target effects in the disruption of these genes, highlighting its therapeutic potential.…”
Get full text

Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience by Aaron Trando, Farid Ghamsari, Philip Yeung, Caitlin Costello, Ila Saunders, Ah-Reum Jeong

“…<b>Background/Objectives:</b> Idecabtagene vicleucel (ide-cel), an anti-B-cell maturation chimeric antigen receptor T-cell therapy, represents an unprecedented treatment option for relapsed/refractory multiple myeloma (R/R MM). …”
Get full text

Nucleotide receptor P2X7/STAT6 pathway regulates macrophage M2 polarization and its application in CAR-T immunotherapy by Qin Si, Lu Yang, Jie Liu, Hui Liu, Ruifang Bu, Na Cui

“…Background: A key factor underlying the failure of Chimeric Antigen Receptor-T Cell (CAR-T) therapy in ovarian cancer (OC) is the presence of an immunosuppressive tumor microenvironment, which is intricately linked to M2 polarization among tumor-infiltrating macrophages. …”
Get full text

Unveiling causal immune cell–gene associations in multiple myeloma: insights from systematic reviews and Mendelian randomization analyses by Hui Zhang, Hui Zhang, Ling Zhang, Jing-Xuan Lian, Zhi-Fu Kou, Yu Zhu, Yu Zhu, Li-Tian Ma, Li-Tian Ma, Jin Zheng, Jin Zheng, Can-Jun Zhao, Can-Jun Zhao

“…BackgroundThe efficacy of novel chimeric antigen receptor T-cell (CAR-T) therapy is inconsistent, likely due to an incomplete understanding of the tumor microenvironment (TME). …”
Get full text

LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells by Shuxian Zhu, Shiyu Zuo, Chuo Li, Xingjie You, Erlie Jiang, Xiaoming Feng, Yuechen Luo

“…We performed cytotoxicity, proliferation, and cytokine assays to evaluate the functionality of universal chimeric antigen receptor-T cell (UCAR-T) cells and conducted in vitro and in vivo assays, including allogeneic responses and RNA sequencing, to assess their resistance to allogeneic T and NK cells, anti-leukemia efficacy, and persistence in treating hematologic malignancies. …”
Get full text

Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell a... by Alice Sýkorová, František Folber, Kamila Polgárová, Heidi Móciková, Juraj Ďuraš, Kateřina Steinerová, Aleš Obr, Adriana Heindorfer, Miriam Ladická, Ľubica Lukáčová, Erika Čellárová, Ivana Plameňová, David Belada, Andrea Janíková, Marek Trněný, Tereza Jančárková, Vít Procházka, Andrej Vranovský, Margaréta Králiková, Jan Vydra, Lukáš Smolej, Ľuboš Drgoňa, Martin Sedmina, Eva Čermáková, Robert Pytlík

“…Abstract Aim The aim of this study was to analyse the outcomes of patients with large B‐cell lymphoma (LBCL) treated with chimeric antigen receptor T‐cell therapy (CAR‐Tx), with a focus on outcomes after CAR T‐cell failure, and to define the risk factors for rapid progression and further treatment. …”
Get full text

Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study by Fiona Reid, Sophie Papa, John Maher, Jean-Pierre Jeannon, James Spicer, Victoria Gibson, Selvam Thavaraj, Michael Metoudi, Christopher Fisher, Nicholas Beckley-Hoelscher, Andrew Hope, Maria Elstad, Antonella Adami, Richard Beatson, Molly Sarah George, Daniela Achkova, Evangelia Williams, Sefina Arif, Abdel Douri, Marc Delord, Mike Lyne, Dharshene Shivapatham, Sakina Gooljar, Arindam Mitra, Linda Gomm, Cienne Morton, Rhonda Henley-Smith, Alice Santambrogio, Cynthia Andoniadou, Sarah Allen, Gary J R Cook, Ana C Parente-Pereira, David M Davies, Farzin Farzaneh, Anna Schurich, Teresa Guerrero-Urbano

“…To target upregulated ErbB dimer expression in this cancer, we developed an autologous CD28-based chimeric antigen receptor T-cell (CAR-T) approach named T4 immunotherapy. …”
Get full text

Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review by Marco Ruella, Guido Ghilardi, Zainul S. Hasanali, Sandra P. Susanibar-Adaniya, Lena E. Winestone, Alfred L. Garfall

“…Chimeric antigen receptor T cell (CAR-T) therapies are now standard-of-care for several B-cell malignancies, and additional indications are being evaluated. …”
Get full text

Application of adoptive cell therapy in malignant melanoma by Qianrong Hu, Jiangying Xuan, Lu Wang, Kangjie Shen, Zixu Gao, Yuhong Zhou, Chuanyuan Wei, Jianying Gu

“…This review discusses the application, efficacy, limitations, as well as future prospects of four commonly utilized approaches -including tumor-infiltrating lymphocytes, chimeric antigen receptor (CAR) T cell, engineered T-cell receptor T cells, and chimeric antigen receptor NK cells- in the context of malignant melanoma.…”
Get full text